Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free AURA Stock Alerts

Aura Biosciences (AURA) Financials

Aura Biosciences logo
$7.61 +0.01 (+0.13%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Aura Biosciences

Annual Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -22 -35 -59 -76 -87 -106
Consolidated Net Income / (Loss)		 -22 -35 -59 -76 -87 -106
Net Income / (Loss) Continuing Operations		 -22 -35 -59 -76 -87 -106
Total Pre-Tax Income 		-22 -35 -59 -76 -87 -106
Total Operating Income		 -22 -35 -60 -85 -96 -113
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 22 35 60 85 96 113
Selling, General & Admin Expense		 4.16 10 18 20 23 22
Research & Development Expense		 18 25 42 65 73 90
Total Other Income / (Expense), net		 0.00 0.01 1.53 8.72 9.31 6.71
Interest Expense		 0.00 -0.01 -1.86 -8.59 -9.43 -6.63
Other Income / (Expense), net		 0.00 -0.00 -0.33 0.13 -0.12 0.08
Income Tax Expense		 - - 0.00 0.14 0.11 0.11
Basic Earnings per Share		 ($82.06) ($8.95) ($1.96) ($1.93) ($1.75) ($1.76)
Weighted Average Basic Shares Outstanding		 367.20K 5.16M 29.94M 39.62M 49.65M 60.34M
Diluted Earnings per Share		 ($82.06) ($8.95) ($1.96) ($1.93) ($1.75) ($1.76)
Weighted Average Diluted Shares Outstanding		 367.20K 5.16M 29.94M 39.62M 49.65M 60.34M
Weighted Average Basic & Diluted Shares Outstanding		 367.20K 5.16M 37.80M 49.50M 50.23M 64.15M

Quarterly Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -19 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34
Consolidated Net Income / (Loss)		 -19 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34
Net Income / (Loss) Continuing Operations		 -19 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34
Total Pre-Tax Income 		-19 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34
Total Operating Income		 -20 -25 -22 -23 -23 -28 -29 -29 -28 -27 -35
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 20 25 22 23 23 28 29 29 28 27 35
Selling, General & Admin Expense		 5.06 4.50 5.26 5.88 6.20 5.47 5.69 5.73 5.73 5.34 6.91
Research & Development Expense		 15 20 17 17 17 22 23 23 22 22 28
Total Other Income / (Expense), net		 1.98 2.79 2.65 2.43 2.23 2.00 1.57 1.64 1.80 1.69 1.19
Interest Expense		 -1.98 -2.61 -2.69 -2.45 -2.26 -2.04 -1.59 -1.68 -1.82 -1.54 -1.19
Other Income / (Expense), net		 -0.01 0.18 -0.03 -0.03 -0.03 -0.04 -0.02 -0.04 -0.01 0.15 0.00
Income Tax Expense		 0.00 0.14 0.05 0.00 0.04 0.02 0.02 0.05 0.03 0.02 0.01
Basic Earnings per Share		 ($0.48) ($0.51) ($0.40) ($0.41) ($0.42) ($0.52) ($0.55) ($0.47) ($0.40) ($0.34) ($0.50)
Weighted Average Basic Shares Outstanding		 38.19M 39.62M 49.45M 49.55M 49.66M 49.65M 50.13M 58.02M 65.94M 60.34M 67.45M
Diluted Earnings per Share		 ($0.48) ($0.51) ($0.40) ($0.41) ($0.42) ($0.52) ($0.55) ($0.47) ($0.40) ($0.34) ($0.50)
Weighted Average Diluted Shares Outstanding		 38.19M 39.62M 49.45M 49.55M 49.66M 49.65M 50.13M 58.02M 65.94M 60.34M 67.45M
Weighted Average Basic & Diluted Shares Outstanding		 38.26M 49.50M 49.54M 49.61M 49.95M 50.23M 50.27M 62.12M 63.50M 64.15M 103.39M

Annual Cash Flow Statements for Aura Biosciences

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -15 132 -27 -81 -9.39 28
Net Cash From Operating Activities		 -24 -32 -55 -64 -80 -85
Net Cash From Continuing Operating Activities		 -24 -32 -55 -64 -80 -85
Net Income / (Loss) Continuing Operations		 -22 -35 -59 -76 -87 -106
Consolidated Net Income / (Loss)		 -22 -35 -59 -76 -87 -106
Depreciation Expense		 0.83 0.83 1.18 1.30 1.22 1.13
Non-Cash Adjustments To Reconcile Net Income		 0.73 2.31 6.09 6.83 8.53 14
Changes in Operating Assets and Liabilities, net		 -3.68 -0.30 -3.10 4.44 -2.64 5.97
Net Cash From Investing Activities		 -0.77 -2.13 -68 -114 69 36
Net Cash From Continuing Investing Activities		 -0.77 -2.13 -68 -114 69 36
Purchase of Property, Plant & Equipment		 -0.77 -2.13 -1.09 -0.71 -1.25 -0.45
Purchase of Investments		 - 0.00 -120 -234 -59 -84
Sale and/or Maturity of Investments		 - 0.00 53 120 129 120
Net Cash From Financing Activities		 10 166 96 97 1.60 77
Net Cash From Continuing Financing Activities		 10 166 96 97 1.60 77
Issuance of Common Equity		 0.00 79 95 96 0.18 76
Other Financing Activities, net		 0.16 0.35 0.43 1.38 1.42 1.01
Effect of Exchange Rate Changes		 - - - - 0.00 -0.19

Quarterly Cash Flow Statements for Aura Biosciences

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 7.85 -15 -15 3.80 -4.67 6.29 6.55 69 -60 12 25
Net Cash From Operating Activities		 -15 -17 -24 -16 -15 -24 -23 -21 -20 -20 -30
Net Cash From Continuing Operating Activities		 -15 -17 -24 -16 -15 -24 -23 -21 -20 -20 -30
Net Income / (Loss) Continuing Operations		 -19 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34
Consolidated Net Income / (Loss)		 -19 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34
Depreciation Expense		 0.34 0.32 0.31 0.31 0.31 0.29 0.29 0.29 0.28 0.27 0.27
Non-Cash Adjustments To Reconcile Net Income		 2.20 2.39 1.52 2.41 2.08 2.53 3.41 3.30 4.33 3.33 3.94
Changes in Operating Assets and Liabilities, net		 0.81 2.03 -6.57 1.49 3.38 -0.94 0.42 2.66 1.31 1.56 -0.43
Net Cash From Investing Activities		 22 -90 9.40 20 9.89 30 30 20 -44 30 55
Net Cash From Continuing Investing Activities		 22 -90 9.27 20 9.89 30 30 20 -44 30 55
Purchase of Property, Plant & Equipment		 -0.09 -0.32 -0.21 -0.40 -0.34 -0.30 -0.19 -0.04 -0.05 -0.18 -0.10
Purchase of Investments		 - -145 -29 -9.90 -20 - 0.00 -9.98 -74 - 0.00
Sale and/or Maturity of Investments		 22 55 39 30 30 30 30 30 30 30 55
Net Cash From Financing Activities		 1.63 93 0.25 0.08 0.72 0.54 0.10 70 4.36 2.77 0.30
Net Cash From Continuing Financing Activities		 1.63 93 0.25 0.08 0.72 0.54 0.10 70 4.36 2.77 0.30
Issuance of Common Equity		 1.42 93 0.10 - 0.08 - 0.10 70 3.36 2.77 0.12
Other Financing Activities, net		 0.20 0.37 0.16 0.08 0.63 0.54 0.00 0.00 1.01 - 0.18
Effect of Exchange Rate Changes		 - - - - - - -0.02 - - -0.16 -0.03

Annual Balance Sheets for Aura Biosciences

This table presents Aura Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 22 160 224 255 183 169
Total Current Assets		 18 154 197 232 161 150
Cash & Equivalents		 17 149 122 41 32 60
Short-Term Investments		 - 0.00 67 185 119 85
Prepaid Expenses		 1.04 4.62 7.87 5.63 9.53 5.50
Plant, Property, & Equipment, net		 3.57 5.25 5.37 3.15 3.22 2.62
Total Noncurrent Assets		 0.08 1.08 22 20 19 17
Other Noncurrent Operating Assets		 0.00 0.95 21 19 18 16
Other Noncurrent Nonoperating Assets		 0.08 0.13 0.77 0.77 0.77 0.77
Total Liabilities & Shareholders' Equity		 22 160 224 255 183 169
Total Liabilities		 2.74 7.72 28 29 31 33
Total Current Liabilities		 2.66 7.36 10 12 15 18
Accounts Payable		 0.61 2.40 2.92 1.79 2.30 1.55
Accrued Expenses		 2.05 4.34 4.57 7.88 9.46 14
Other Current Liabilities		 0.00 0.62 2.96 2.69 3.15 3.24
Total Noncurrent Liabilities		 0.08 0.36 18 17 16 14
Other Noncurrent Operating Liabilities		 0.07 0.36 18 17 16 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -109 152 196 226 152 137
Total Preferred & Common Equity		 -109 152 196 226 152 137
Total Common Equity		 -109 152 196 226 152 137
Common Stock		 8.17 304 407 513 526 617
Retained Earnings		 -117 -152 -211 -287 -374 -480
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.07 0.54 0.26 -0.10

Quarterly Balance Sheets for Aura Biosciences

This table presents Aura Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 143 206 193 180 235 218 205 155 204 190 138
Total Current Assets		 116 179 166 154 212 196 183 135 184 170 119
Cash & Equivalents		 61 38 48 56 26 30 25 38 107 48 85
Short-Term Investments		 50 135 114 93 177 157 149 90 70 114 30
Prepaid Expenses		 4.21 5.58 4.18 4.81 9.38 8.18 9.10 6.53 6.65 8.25 3.77
Plant, Property, & Equipment, net		 5.48 5.17 5.06 4.86 3.05 3.33 3.33 3.11 2.86 2.63 2.47
Total Noncurrent Assets		 22 22 21 21 20 19 19 18 18 17 17
Other Noncurrent Operating Assets		 21 21 21 20 19 19 18 17 17 17 16
Other Noncurrent Nonoperating Assets		 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77
Total Liabilities & Shareholders' Equity		 143 206 193 180 235 218 205 155 204 190 138
Total Liabilities		 28 26 26 28 26 27 31 27 30 33 30
Total Current Liabilities		 9.96 8.11 8.90 11 9.66 11 15 12 15 19 17
Accounts Payable		 1.72 1.06 0.55 1.49 1.93 1.46 1.99 2.01 1.29 1.89 2.57
Accrued Expenses		 5.30 4.07 5.33 6.37 4.99 6.34 9.60 6.99 10 14 11
Other Current Liabilities		 2.94 2.99 3.01 3.04 2.74 2.75 3.13 3.17 3.20 3.22 3.27
Total Noncurrent Liabilities		 18 18 17 17 17 16 16 15 15 15 14
Other Noncurrent Operating Liabilities		 18 18 17 17 17 16 16 15 15 15 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 115 180 166 152 209 191 175 128 175 157 107
Total Preferred & Common Equity		 115 180 166 152 209 191 175 128 175 157 107
Total Common Equity		 115 180 166 152 209 191 175 128 175 157 107
Common Stock		 310 409 413 417 516 519 522 530 603 611 622
Retained Earnings		 -194 -228 -247 -265 -307 -327 -348 -402 -429 -455 -514
Accumulated Other Comprehensive Income / (Loss)		 -0.15 -0.05 -0.22 -0.13 0.02 -0.18 0.61 0.11 0.03 0.07 -0.21

Annual Metrics And Ratios for Aura Biosciences

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 29,210,549.00 - - - 63,503,269.00
DEI Adjusted Shares Outstanding		 0.00 29,210,549.00 - - - 63,503,269.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.21 - - - -1.67
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -61.06% -72.71% -40.56% -13.70% -17.44%
EBIT Growth		 0.00% -58.78% -71.98% -39.97% -13.41% -17.12%
NOPAT Growth		 0.00% -58.74% -71.05% -40.96% -13.09% -17.35%
Net Income Growth		 0.00% -58.75% -66.70% -30.03% -13.76% -22.17%
EPS Growth		 0.00% 89.09% 78.10% 1.53% 9.33% -0.57%
Operating Cash Flow Growth		 0.00% -33.26% -68.47% -16.93% -24.99% -6.19%
Free Cash Flow Firm Growth		 0.00% 0.00% -74.06% -16.27% -30.63% -3.32%
Invested Capital Growth		 0.00% 65.46% 92.78% -118.20% 109.92% -7,596.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -24.84% -9.11% -3.57% 0.66%
EBIT Q/Q Growth		 0.00% 0.00% -24.48% -8.96% -3.49% 0.67%
NOPAT Q/Q Growth		 0.00% 0.00% -24.63% -9.21% -3.25% 0.50%
Net Income Q/Q Growth		 0.00% 0.00% -9.15% -7.87% -4.45% 0.26%
EPS Q/Q Growth		 0.00% 0.00% -102.92% 0.52% -0.57% 9.28%
Operating Cash Flow Q/Q Growth		 0.00% -34.59% -12.18% 0.97% -8.96% 3.95%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 2.50% -9.02% 4.22%
Invested Capital Q/Q Growth		 0.00% 0.00% 131.49% -158.11% 122.64% -35.68%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.03% 100.00% 100.18% 100.13% 100.10%
Interest Burden Percent		 100.01% 99.96% 96.93% 89.88% 90.20% 94.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -114.68% -41.07% -33.78% -36.26% -46.01% -73.52%
Cash Return on Invested Capital (CROIC)		 0.00% -1,040.28% -992.22% 0.00% -63,405.74% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 643.88% -10.43% -33.78% -36.26% -46.01% -73.52%
Return on Equity Simple (ROE_SIMPLE)		 20.43% -23.14% -30.05% -33.83% -57.19% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -25 -42 -59 -67 -79
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -38.10% -12.69% -9.77% -8.12% -10.37% -18.35%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -26.34% -44.27% -57.67%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -35 -61 -85 -96 -113
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -34 -59 -84 -95 -112
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 3.26 1.57 1.50 2.70 2.53
Price to Tangible Book Value (P/TBV)		 0.00 3.26 1.57 1.50 2.70 2.53
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 99.29 111.76 19.92 0.00 2,402.84 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.97 -0.97 -0.99 -1.00 -1.03
Leverage Ratio		 1.14 1.06 1.10 1.14 1.16 1.22
Compound Leverage Factor		 1.14 1.06 1.07 1.02 1.04 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 661.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -561.45% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.69 37.61 5.30 5.32 4.42 1.15
Noncontrolling Interest Sharing Ratio		 661.45% 74.60% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 6.94 20.90 18.81 18.76 10.77 8.15
Quick Ratio		 6.54 20.27 18.06 18.30 10.13 7.85
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -26 -45 -52 -68 -71
Operating Cash Flow to CapEx		 -3,154.47% -1,525.18% -4,990.95% -9,005.22% -6,369.11% -18,957.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -8,107.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -8,364.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 1.88 3.10 5.98 -1.09 0.11 -8.10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.23 2.88 -7.07 1.20 -8.20
Enterprise Value (EV)		 186 347 119 113 260 202
Market Capitalization		 76 496 308 339 411 346
Book Value per Share		 ($296.06) $5.21 $6.67 $5.90 $3.04 $2.16
Tangible Book Value per Share		 ($296.06) $5.21 $6.67 $5.90 $3.04 $2.16
Total Capital		 19 152 196 226 152 137
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -17 -149 -189 -226 -151 -144
Capital Expenditures (CapEx)		 0.77 2.13 1.09 0.71 1.25 0.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.62 -2.74 -2.59 -6.73 -5.38 -13
Debt-free Net Working Capital (DFNWC)		 16 146 186 219 146 131
Net Working Capital (NWC)		 16 146 186 219 146 131
Net Nonoperating Expense (NNE)		 6.66 11 17 17 20 27
Net Nonoperating Obligations (NNO)		 -17 -149 -190 -227 -152 -145
Total Depreciation and Amortization (D&A)		 0.83 0.83 1.18 1.30 1.22 1.13
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.95) ($1.96) ($1.93) ($1.75) ($1.76)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 29.22M 29.94M 39.62M 49.65M 60.34M
Adjusted Diluted Earnings per Share		 $0.00 ($8.95) ($1.96) ($1.93) ($1.75) ($1.76)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 29.22M 29.94M 39.62M 49.65M 60.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($8.95) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 5.16M 37.80M 49.50M 50.23M 64.15M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -25 -42 -59 -67 -79
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -7,401.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -5,181.40 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -7,658.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -5,438.40 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Aura Biosciences

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 50,225,312.00 50,268,758.00 62,119,873.00 63,503,269.00 64,150,468.00
DEI Adjusted Shares Outstanding		 - - - - - - 50,225,312.00 50,268,758.00 62,119,873.00 63,503,269.00 64,150,468.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.55 -0.54 -0.42 -0.40 -0.53
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -25.30% -40.33% -15.21% -12.33% -13.87% -13.50% -30.53% -26.20% -20.46% 2.69% -20.24%
EBIT Growth		 -25.08% -39.60% -14.84% -12.21% -13.49% -13.19% -30.05% -25.72% -20.05% 2.73% -19.98%
NOPAT Growth		 -27.61% -40.71% -14.76% -12.26% -13.39% -12.21% -30.13% -25.71% -20.12% 2.06% -20.08%
Net Income Growth		 -16.42% -33.65% -12.82% -11.14% -13.67% -16.73% -39.47% -32.86% -24.18% 1.06% -22.57%
EPS Growth		 11.11% 1.92% 13.04% 14.58% 12.50% -1.96% -37.50% -14.63% 4.76% 34.62% 9.09%
Operating Cash Flow Growth		 -43.15% 3.48% -48.99% -10.13% 0.84% -37.76% 4.49% -28.81% -31.89% 14.54% -27.99%
Free Cash Flow Firm Growth		 -18.44% 32.44% -24.45% -32.04% -2.06% -101.10% 2.85% 14.51% -0.95% 47.43% -17.75%
Invested Capital Growth		 -27.50% -118.20% -13.57% -10.07% -125.45% 109.92% -115.43% -205.50% -1,150.94% -7,596.30% -940.86%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.71% -20.48% 9.22% -1.98% -2.09% -20.10% -4.40% 1.41% 2.55% 2.98% -29.00%
EBIT Q/Q Growth		 -0.91% -20.05% 9.17% -1.98% -2.06% -19.73% -4.36% 1.41% 2.55% 2.98% -28.71%
NOPAT Q/Q Growth		 -1.05% -20.96% 9.97% -2.01% -2.06% -19.70% -4.41% 1.45% 2.47% 2.40% -28.01%
Net Income Q/Q Growth		 -1.16% -19.55% 10.96% -3.20% -3.47% -22.77% -6.38% 1.69% 3.29% 2.19% -31.79%
EPS Q/Q Growth		 0.00% -6.25% 21.57% -2.50% -2.44% -23.81% -5.77% 14.55% 14.89% 15.00% -47.06%
Operating Cash Flow Q/Q Growth		 -5.18% -12.88% -40.63% 34.04% 5.30% -56.83% 2.49% 11.05% 3.03% -1.61% -46.04%
Free Cash Flow Firm Q/Q Growth		 -15.61% 24.62% -44.16% -5.10% 10.64% -48.54% 30.36% 7.51% -5.52% 22.66% -56.01%
Invested Capital Q/Q Growth		 -48.46% -158.11% 572.08% -36.39% -114.59% 122.64% -834.26% -335.06% -72.96% -35.68% -1.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.62% 100.23% 100.00% 100.20% 100.09% 100.07% 100.18% 100.10% 100.06% 100.03%
Interest Burden Percent		 90.33% 89.40% 87.98% 89.24% 90.29% 92.69% 94.51% 94.14% 93.50% 94.30% 96.59%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -53.11% -36.26% -40.43% -45.09% -50.99% -46.01% -56.24% -55.39% -64.26% -73.52% -95.57%
Cash Return on Invested Capital (CROIC)		 -2,411.47% 0.00% -1,094.69% -1,820.92% 0.00% -63,405.74% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -53.11% -36.26% -40.43% -45.09% -50.99% -46.01% -56.24% -55.39% -64.26% -73.52% -95.57%
Return on Equity Simple (ROE_SIMPLE)		 -46.69% 0.00% -37.67% -42.14% -47.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -17 -16 -16 -16 -19 -20 -20 -20 -19 -24
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.18% -2.30% -2.16% -2.51% -2.94% -3.36% -4.31% -3.82% -3.91% -4.37% -7.60%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.68% - - - -12.81% -15.88% -11.47% -12.47% -13.93% -22.76%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -25 -22 -23 -23 -28 -29 -29 -28 -27 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -24 -22 -22 -23 -28 -29 -28 -28 -27 -35
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.26 1.50 1.86 1.96 2.53 2.70 2.30 1.80 2.45 2.53 4.00
Price to Tangible Book Value (P/TBV)		 2.26 1.50 1.86 1.96 2.53 2.70 2.30 1.80 2.45 2.53 4.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 103.28 0.00 36.13 57.23 0.00 2,402.84 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.99 -0.97 -0.98 -1.00 -1.00 -0.99 -1.00 -1.02 -1.03 -1.04
Leverage Ratio		 1.21 1.14 1.13 1.15 1.18 1.16 1.16 1.15 1.19 1.22 1.25
Compound Leverage Factor		 1.09 1.02 1.00 1.02 1.07 1.07 1.10 1.09 1.12 1.15 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.84 6.10 7.78 6.95 6.88 5.65 3.15 3.94 4.02 2.82 3.29
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.13 18.76 21.97 18.54 12.47 10.77 11.06 12.39 9.04 8.15 7.09
Quick Ratio		 13.68 18.30 20.99 17.77 11.85 10.13 10.52 11.94 8.60 7.85 6.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -10 -15 -16 -14 -21 -14 -13 -14 -11 -17
Operating Cash Flow to CapEx		 -17,114.44% -5,484.86% -11,643.81% -4,001.99% -4,478.89% -8,010.70% -12,489.30% -53,266.67% -44,764.44% -11,630.11% -29,306.86%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.87 -1.09 5.14 3.27 -0.48 0.11 -0.79 -3.45 -5.97 -8.10 -8.25
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.71 -7.07 -0.81 -0.37 -2.35 1.20 -5.93 -6.72 -5.49 -8.20 -7.46
Enterprise Value (EV)		 194 113 186 187 268 260 166 137 222 202 314
Market Capitalization		 343 339 389 375 442 411 294 315 384 346 429
Book Value per Share		 $3.97 $5.90 $4.22 $3.86 $3.52 $3.04 $2.55 $3.47 $2.52 $2.16 $1.67
Tangible Book Value per Share		 $3.97 $5.90 $4.22 $3.86 $3.52 $3.04 $2.55 $3.47 $2.52 $2.16 $1.67
Total Capital		 152 226 209 191 175 152 128 175 157 137 107
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -149 -226 -203 -187 -174 -151 -128 -177 -162 -144 -115
Capital Expenditures (CapEx)		 0.09 0.32 0.21 0.40 0.34 0.30 0.19 0.04 0.05 0.18 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.08 -6.73 -0.29 -2.37 -5.61 -5.38 -5.64 -8.21 -11 -13 -13
Debt-free Net Working Capital (DFNWC)		 143 219 203 185 169 146 122 169 151 131 102
Net Working Capital (NWC)		 143 219 203 185 169 146 122 169 151 131 102
Net Nonoperating Expense (NNE)		 4.17 4.78 4.09 4.40 4.78 6.37 7.16 6.99 6.60 6.49 9.28
Net Nonoperating Obligations (NNO)		 -150 -227 -204 -188 -175 -152 -129 -178 -163 -145 -116
Total Depreciation and Amortization (D&A)		 0.34 0.32 0.31 0.31 0.31 0.29 0.29 0.29 0.28 0.27 0.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.48) ($0.51) ($0.40) ($0.41) ($0.42) ($0.52) ($0.55) ($0.47) ($0.40) ($0.34) ($0.50)
Adjusted Weighted Average Basic Shares Outstanding		 38.19M 39.62M 49.45M 49.55M 49.66M 49.65M 50.13M 58.02M 65.94M 60.34M 67.45M
Adjusted Diluted Earnings per Share		 ($0.48) ($0.51) ($0.40) ($0.41) ($0.42) ($0.52) ($0.55) ($0.47) ($0.40) ($0.34) ($0.50)
Adjusted Weighted Average Diluted Shares Outstanding		 38.19M 39.62M 49.45M 49.55M 49.66M 49.65M 50.13M 58.02M 65.94M 60.34M 67.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.26M 49.50M 49.54M 49.61M 49.95M 50.23M 50.27M 62.12M 63.50M 64.15M 103.39M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -17 -16 -16 -16 -19 -20 -20 -20 -19 -24
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Aura Biosciences (NASDAQ: AURA) remains a pre-revenue biotech with a very strong cash position, but its quarterly burn is still substantial and operating losses continue to widen year over year. The company ended Q1 2026 with a balance sheet that gives it room to fund development, though investors should still watch the pace of cash use closely.

  • Cash and investments remain sizable: Aura reported $84.8 million in cash and equivalents and $29.9 million in short-term investments at the end of Q1 2026, for roughly $114.7 million of liquid resources.
  • Liquidity is still comfortable relative to liabilities: Total current assets were $118.5 million versus total current liabilities of $16.7 million, supporting a solid near-term funding cushion.
  • No revenue, but the balance sheet is intact: The company still had no product revenue, which is expected for a clinical-stage biotech, but it also avoided any major balance-sheet stress in the latest quarter.
  • Shareholder equity remains positive: Total common equity was $107.2 million in Q1 2026, indicating the company is not yet in a distressed equity position.
  • Investing activity boosted cash in Q1 2026: Aura generated $54.9 million of net cash from investing activities, mainly from $55.0 million in sales/maturities of investments.
  • Operating spending is still heavy: Q1 2026 research and development expense was $28.0 million and SG&A was $6.9 million, leading to $34.9 million in operating expenses for the quarter.
  • Losses remain large: Net loss in Q1 2026 was $33.7 million, or $0.50 per share, showing the business is still far from profitability.
  • Cash from operations stayed deeply negative: Operating cash flow was negative $29.9 million in Q1 2026, which is consistent with a development-stage biotech burning cash to advance trials.
  • Shares outstanding have trended higher over time: Weighted average basic shares rose to 67.4 million in Q1 2026 from 50.1 million in Q1 2025, suggesting ongoing dilution from financing activity.
  • Cash balance fell sharply from year-end 2025: Cash and equivalents dropped from $107.4 million in Q2 2025 to $84.8 million in Q1 2026, even after including investment sales.
  • Recent quarters show a worsening loss trend: Quarterly net losses widened from $25.6 million in Q4 2025 to $33.7 million in Q1 2026.
  • Operating losses have increased versus last year: Q1 2026 operating loss of $34.9 million was worse than the $29.0 million operating loss in Q1 2025.
  • Retained earnings remain deeply negative: Retained earnings were negative $514.1 million, underscoring the long history of cumulative losses.

Bottom line: Aura Biosciences has enough liquidity to keep advancing its pipeline for now, but the financial picture is still defined by heavy R&D spending, recurring losses, and reliance on its cash reserve. For retail investors, the key question is whether upcoming clinical progress can justify the ongoing burn rate before another capital raise becomes necessary.

05/26/26 11:47 PM ETAI Generated. May Contain Errors.

Aura Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aura Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Aura Biosciences' net income appears to be on an upward trend, with a most recent value of -$106.19 million in 2025, rising from -$22.21 million in 2020. The previous period was -$86.92 million in 2024. View Aura Biosciences' forecast to see where analysts expect Aura Biosciences to go next.

Aura Biosciences' total operating income in 2025 was -$112.79 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $112.79 million

Over the last 5 years, Aura Biosciences' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Aura Biosciences' total liabilities were at $32.52 million at the end of 2025, a 6.5% increase from 2024, and a 1,086.3% increase since 2020.

In the past 5 years, Aura Biosciences' cash and equivalents has ranged from $17.39 million in 2020 to $149.06 million in 2021, and is currently $59.52 million as of their latest financial filing in 2025.

Over the last 5 years, Aura Biosciences' book value per share changed from -296.06 in 2020 to 2.16 in 2025, a change of -100.7%.


Related Companies

Financial statements for NASDAQ:AURA last updated on 5/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
The digital asset institutions are buying before headlines hit
JPMorgan is processing $2 billion a day through new digital rails. BlackRock's tokenized fund crossed $2.8 bil...
Awesomely, LLC | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Trump Is Eyeing the Biggest Monetary Shift Since Nixon
On August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...
Americas Gold Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Elon Confirms SpaceX IPO For 6/12 [Act Now!]
Elon Musk has confirmed SpaceX will IPO on Friday, June 12, 2026, at a valuation of up to $2 trillion - potent...
Paradigm Press | Sponsoredtc pixel